An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

The goal of this single arm ,non-interventional, prospective, descriptive study is to evaluate the efficacy of guselkumab treatment in preventing endoscopic recurrence of Crohn's Disease in adult participants who have a documented diagnosis of moderate to severe CD and have undergone an ileocolonic surgical resection. The primary endpoint is Endoscopic recurrence rate at week24.

NCT Number	NCT07528040
Lead Sponsor	Shanghai 10th People's Hospital Collaborators: Xian-Janssen Pharmaceutical Ltd.
Conditions	Crohn's Disease (CD)
Enrollment	88 participants
Start Date	2026-04-15
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-14